Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Korea United Pharm Inc. (033270.KS)
KRW17,770.00
+330.00 (+1.89%)
KR KSC Healthcare Drug Manufacturers - Specialty & Generic
Address
Nonhyeon-ro 121street 22
Seoul, KR
Seoul, KR
CEO
Duk-Young Kang
Website
kup.co.kr
IPO
2000-02-11
ISIN KR7033270000
Description
Korea United Pharm Inc. is a South Korean enterprise dedicated to the development, production, and distribution of a wide array of pharmaceutical products. The company's extensive portfolio encompasses therapeutic solutions for various medical fields, such as the respiratory, musculoskeletal, gastrointestinal, cardiovascular, and central nervous systems, in addition to treatments for cancer, infections, allergies, and immune disorders. It also supplies over-the-counter drugs. While deeply rooted in the South Korean market, the firm extends its reach internationally, exporting its medications to nearly 40 countries. Founded in 1987, Korea United Pharm Inc. is headquartered in Seoul, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW17,770.00
+330.00 (+1.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
31.6K
Beta
0.32
Float Shares
8.39M
Free Float %
58.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54% | -4.92% | -8.17% | -7.48% | -5.26% | -2.27% | -11.88% | -17.92% | -65.84% | -11.88% | +373.02% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
17,770.00
DCF (Unlevered)
68,263.34
+284.1%
DCF (Levered)
75,948.03
+327.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.87
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A+
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.0% Q1'26: +3.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+18.5% ★ Q1'26: +2.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+14.3% ★ Q1'26: +14.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+16.9% ★ Q1'26: +14.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+12.1% ★ Q1'26: +11.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+10.9% Q1'26: -2.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.23× ★ Q1'26: 0.25× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
162.05B
est: 163.23B (-0.7%)
|
176.91B
est: 163.23B (+8.4%)
|
197.02B
est: 177.10B (+11.2%)
|
211.94B
est: 197.03B (+7.6%)
|
221.31B
est: 210.10B (+5.3%)
|
215.95B
est: 224.95B (-4.0%)
|
221.04B
est: 75.00B (+194.7%)
|
262.52B
est: 236.60B (+11.0%)
|
288.71B
est: 302.30B (-4.5%)
|
288.76B
est: 291.00B (-0.8%)
|
300.60B
300.60B – 300.60B
+3.3% YoY
|
317.30B
317.30B – 317.30B
+5.6% YoY
|
335.30B
335.30B – 335.30B
+5.7% YoY
|
| EBITDA |
32.16B
est: 35.93B (-10.5%)
|
34.63B
est: 35.93B (-3.6%)
|
36.17B
est: 38.98B (-7.2%)
|
47.64B
est: 43.37B (+9.8%)
|
44.97B
est: 46.25B (-2.8%)
|
43.27B
est: 49.52B (-12.6%)
|
46.61B
est: 16.51B (+182.3%)
|
61.77B
est: 52.08B (+18.6%)
|
57.84B
est: 67.09B (-13.8%)
|
60.47B
est: 64.58B (-6.4%)
|
66.71B
66.71B – 66.71B
+3.3% YoY
|
70.42B
70.42B – 70.42B
+5.6% YoY
|
74.41B
74.41B – 74.41B
+5.7% YoY
|
| EBIT |
25.54B
est: 30.02B (-14.9%)
|
27.46B
est: 30.02B (-8.5%)
|
28.96B
est: 32.57B (-11.1%)
|
40.54B
est: 36.23B (+11.9%)
|
37.94B
est: 38.64B (-1.8%)
|
34.77B
est: 41.37B (-15.9%)
|
39.22B
est: 13.79B (+184.4%)
|
53.06B
est: 43.51B (+21.9%)
|
46.57B
est: 56.10B (-17.0%)
|
48.91B
est: 54.00B (-9.4%)
|
55.78B
55.78B – 55.78B
+3.3% YoY
|
58.88B
58.88B – 58.88B
+5.6% YoY
|
62.22B
62.22B – 62.22B
+5.7% YoY
|
| Net Income |
21.72B
est: 17.83B (+21.8%)
|
19.51B
est: 17.83B (+9.5%)
|
27.86B
est: 16.46B (+69.2%)
|
31.67B
est: 25.12B (+26.1%)
|
30.92B
est: 28.85B (+7.2%)
|
26.61B
est: 28.80B (-7.6%)
|
28.65B
est: 8.03B (+257.0%)
|
45.28B
est: 28.73B (+57.6%)
|
32.45B
est: 65.14B (-50.2%)
|
38.31B
est: 37.19B (+3.0%)
|
46.45B
46.45B – 46.45B
+24.9% YoY
|
47.58B
47.58B – 47.58B
+2.4% YoY
|
50.19B
50.19B – 50.19B
+5.5% YoY
|
| SGA |
29.21B
est: 22.98B (+27.1%)
|
31.72B
est: 22.98B (+38.0%)
|
34.33B
est: 24.94B (+37.7%)
|
34.99B
est: 27.74B (+26.1%)
|
38.89B
est: 29.58B (+31.5%)
|
32.91B
est: 31.67B (+3.9%)
|
33.82B
est: 10.56B (+220.2%)
|
34.69B
est: 33.31B (+4.1%)
|
38.89B
est: 41.58B (-6.5%)
|
39.31B
est: 40.03B (-1.8%)
|
41.35B
41.35B – 41.35B
+3.3% YoY
|
43.64B
43.64B – 43.64B
+5.6% YoY
|
46.12B
46.12B – 46.12B
+5.7% YoY
|
| EPS |
1,384.00
est: 1,210.67 (+14.3%)
|
1,277.00
est: 1,210.67 (+5.5%)
|
1,882.00
est: 1,118.00 (+68.3%)
|
2,139.20
est: 1,705.67 (+25.4%)
|
2,086.92
est: 1,959.00 (+6.5%)
|
1,793.76
est: 1,956.00 (-8.3%)
|
1,930.09
est: 545.00 (+254.1%)
|
3,057.78
est: 1,951.00 (+56.7%)
|
2,206.00
est: 3,988.00 (-44.7%)
|
2,614.37
est: 2,277.00 (+14.8%)
|
2,844.00
2,844.00 – 2,844.00
+24.9% YoY
|
2,913.00
2,913.00 – 2,913.00
+2.4% YoY
|
3,073.00
3,073.00 – 3,073.00
+5.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-26 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-22 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-30 | A+ | 5/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | A+ | 5/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-28 | A+ | 5/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
29.78B
OE per share TTM
1,889.59
Owner's Yield
10.09%
Maintenance CapEx ratio
168.23%
Maint CapEx / Avg PPE
55.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 31 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.05% | 816.9K | 0.58% |
| 2 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.02% | 7.4K | 0.54% |
| 3 | Kodex KOSPI 226490.KS | 0.01% | 60.7K | 0.15% |
| 4 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 82.6K | 0.24% |
| 5 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 82.6K | 0.24% |
| 6 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 9.4K | 0.56% |
| 7 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 12.0K | 0.44% |
| 8 | Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO | 0.00% | 127.5K | 0.23% |
| 9 | Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO | 0.00% | 11.0K | 0.22% |
| 10 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 131.4K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
52.26M
Shares Outstanding
14.44M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Duk-Young Kang | Chief Executive Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 033270.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
